Last reviewed · How we verify
Ranibizumab Intravitreal injections
Ranibizumab Intravitreal injections is a Small molecule drug developed by Novartis Pharmaceuticals. It is currently FDA-approved.
At a glance
| Generic name | Ranibizumab Intravitreal injections |
|---|---|
| Sponsor | Novartis Pharmaceuticals |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia (PHASE3)
- Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema (PHASE3)
- A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) (PHASE4)
- A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME (PHASE3)
- A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD (PHASE3)
- A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PHASE3)
- Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ranibizumab Intravitreal injections CI brief — competitive landscape report
- Ranibizumab Intravitreal injections updates RSS · CI watch RSS
- Novartis Pharmaceuticals portfolio CI
Frequently asked questions about Ranibizumab Intravitreal injections
What is Ranibizumab Intravitreal injections?
Ranibizumab Intravitreal injections is a Small molecule drug developed by Novartis Pharmaceuticals.
Who makes Ranibizumab Intravitreal injections?
Ranibizumab Intravitreal injections is developed and marketed by Novartis Pharmaceuticals (see full Novartis Pharmaceuticals pipeline at /company/novartis-pharmaceuticals).
What development phase is Ranibizumab Intravitreal injections in?
Ranibizumab Intravitreal injections is FDA-approved (marketed).